Merck (NYSE: MRK) reported Q1 EPS of $2.07, $0.14 better than the analyst estimate of $1.93. Revenue for the quarter came in at $15.8 billion versus the consensus estimate of $15.22 billion.

GUIDANCE:

Merck sees FY2024 EPS of $8.53-$8.65, versus the consensus of $8.56. Merck sees FY2024 revenue of $63.1-64.3 billion, versus the consensus of $63.8 billion.

For earnings history and earnings-related data on Merck (MRK) click here.